tradingkey.logo

礼来

LLY
1058.180USD
+37.340+3.66%
收盘 02/06, 16:00美东报价延迟15分钟
1.00T总市值
46.11市盈率 TTM

礼来

1058.180
+37.340+3.66%

关于 礼来 公司

礼来公司是全球知名的创新药物巨头,专注于在人用医药领域的研发、制造与销售。其糖尿病、肥胖及心脏代谢线代表药品含 Basaglar、Humalog、Mounjaro、Trulicity 与 Zepbound(体重管理);肿瘤产品涵盖 Alimta、Retevmo、Tyvyt、Verzenio;免疫学阵容包含 Ebglyss、Olumiant、Omvoh、Taltz;神经科学线提供 Cymbalta、Emgality;其他重点品牌及疗法尚有 Cialis、Forteo。公司透过 POINT Biopharma 深耕放射性药物研发,并开发 α4β7 抑制剂 MORF-057 治疗 IBD,同时投资 AI 药物设计与数字临床平台以加速候选药上市。

礼来简介

公司代码LLY
公司名称Eli Lilly and Co
上市日期Jul 09, 1970
CEORicks (David A)
员工数量47000
证券类型Ordinary Share
年结日Jul 09
公司地址Lilly Corporate Ctr
城市INDIANAPOLIS
上市交易所NASDAQ OMX NASDAQ Basic NYSE
国家United States of America
邮编46285
电话13172762000
网址https://www.lilly.com/
公司代码LLY
上市日期Jul 09, 1970
CEORicks (David A)

礼来公司高管

名称
名称/职务
职务
持股
持股变动
Mr. J. Erik Fyrwald
Mr. J. Erik Fyrwald
Independent Director
Independent Director
74.59K
+10.00%
Ms. Anne E. White
Ms. Anne E. White
Executive Vice President, President - Lilly Neuroscience
Executive Vice President, President - Lilly Neuroscience
74.21K
+8641.00%
Mr. Patrik Jonsson
Mr. Patrik Jonsson
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
54.13K
+9067.00%
Mr. Edgardo Hernandez
Mr. Edgardo Hernandez
Executive Vice President, President - Manufacturing Operations
Executive Vice President, President - Manufacturing Operations
39.73K
-17.00%
Mr. Ilya Yuffa
Mr. Ilya Yuffa
Executive Vice President, President of Lilly International
Executive Vice President, President of Lilly International
26.26K
-1250.00%
Ms. Anat Hakim
Ms. Anat Hakim
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
25.66K
-17875.00%
Dr. Katherine Baicker, Ph.D.
Dr. Katherine Baicker, Ph.D.
Independent Director
Independent Director
23.37K
+215.00%
Mr. Diogo Rau
Mr. Diogo Rau
Executive Vice President, Chief Information and Digital Officer
Executive Vice President, Chief Information and Digital Officer
19.72K
+8618.00%
Mr. Lucas E. Montarce
Mr. Lucas E. Montarce
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
14.69K
+715.00%
Mr. Eric Dozier
Mr. Eric Dozier
Executive Vice President, Chief People Officer
Executive Vice President, Chief People Officer
9.84K
+1337.00%
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. J. Erik Fyrwald
Mr. J. Erik Fyrwald
Independent Director
Independent Director
74.59K
+10.00%
Ms. Anne E. White
Ms. Anne E. White
Executive Vice President, President - Lilly Neuroscience
Executive Vice President, President - Lilly Neuroscience
74.21K
+8641.00%
Mr. Patrik Jonsson
Mr. Patrik Jonsson
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
54.13K
+9067.00%
Mr. Edgardo Hernandez
Mr. Edgardo Hernandez
Executive Vice President, President - Manufacturing Operations
Executive Vice President, President - Manufacturing Operations
39.73K
-17.00%
Mr. Ilya Yuffa
Mr. Ilya Yuffa
Executive Vice President, President of Lilly International
Executive Vice President, President of Lilly International
26.26K
-1250.00%
Ms. Anat Hakim
Ms. Anat Hakim
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
25.66K
-17875.00%

收入明细

单位: USD更新时间: 1月6日 周二
单位: USD更新时间: 1月6日 周二
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
Diabetes-Mounjaro
6.52B
37.02%
Diabetes-Zepbound
3.59B
20.39%
Oncology-Verzenio
1.47B
8.35%
Diabetes-Other Diabetes
1.06B
6.04%
Diabetes-Trulicity
1.05B
5.98%
其他
3.91B
22.23%
地区USD
名称
营收
占比
U.S.
11.30B
64.20%
Europe
3.50B
19.87%
Other foreign countries
1.69B
9.59%
China
560.40M
3.18%
Japan
554.70M
3.15%
业务
地区
业务USD
名称
营收
占比
Diabetes-Mounjaro
6.52B
37.02%
Diabetes-Zepbound
3.59B
20.39%
Oncology-Verzenio
1.47B
8.35%
Diabetes-Other Diabetes
1.06B
6.04%
Diabetes-Trulicity
1.05B
5.98%
其他
3.91B
22.23%

股东统计

更新时间: 11月12日 周三
更新时间: 11月12日 周三
持股股东
股东类型
持股股东
持股股东
占比
Lilly Endowment, Inc.
9.72%
The Vanguard Group, Inc.
8.63%
PNC Investments LLC
5.41%
BlackRock Institutional Trust Company, N.A.
4.43%
State Street Investment Management (US)
3.67%
其他
68.13%
持股股东
持股股东
占比
Lilly Endowment, Inc.
9.72%
The Vanguard Group, Inc.
8.63%
PNC Investments LLC
5.41%
BlackRock Institutional Trust Company, N.A.
4.43%
State Street Investment Management (US)
3.67%
其他
68.13%
股东类型
持股股东
占比
Investment Advisor
45.55%
Investment Advisor/Hedge Fund
18.81%
Foundation
9.72%
Research Firm
2.04%
Pension Fund
1.95%
Bank and Trust
1.76%
Insurance Company
1.47%
Sovereign Wealth Fund
1.29%
Hedge Fund
0.74%
其他
16.68%

机构持股

更新时间: 1月1日 周四
更新时间: 1月1日 周四
报告期
机构数
持股数
持股占比
持股变动
2025Q4
5966
788.98M
83.44%
-4.91M
2025Q3
5762
789.85M
83.53%
-6.48M
2025Q2
5717
798.76M
84.28%
+2.87M
2025Q1
5710
800.38M
84.44%
+5.04M
2024Q4
5528
795.43M
83.87%
+627.51K
2024Q3
5177
793.57M
83.49%
-5.03M
2024Q2
5068
795.80M
83.72%
-2.01M
2024Q1
4916
795.04M
83.62%
-6.22M
2023Q4
4670
799.46M
84.21%
-2.37M
2023Q3
4354
800.21M
84.30%
-1.19M
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
Lilly Endowment, Inc.
92.19M
9.75%
-6.46K
-0.01%
Dec 29, 2025
The Vanguard Group, Inc.
80.59M
8.52%
+541.95K
+0.68%
Sep 30, 2025
PNC Investments LLC
51.15M
5.41%
+70.46K
+0.14%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
41.90M
4.43%
+599.55K
+1.45%
Sep 30, 2025
State Street Investment Management (US)
34.73M
3.67%
+219.59K
+0.64%
Sep 30, 2025
Capital Research Global Investors
25.09M
2.65%
+4.33M
+20.87%
Sep 30, 2025
Fidelity Management & Research Company LLC
22.69M
2.4%
-1.67M
-6.86%
Sep 30, 2025
Geode Capital Management, L.L.C.
19.82M
2.1%
+1.69M
+9.32%
Sep 30, 2025
Capital World Investors
14.97M
1.58%
-2.66M
-15.11%
Sep 30, 2025
Wellington Management Company, LLP
14.56M
1.54%
+574.23K
+4.10%
Sep 30, 2025
查看更多

持股ETF

更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
VanEck Pharmaceutical ETF
47.56%
iShares U.S. Pharmaceuticals ETF
25.23%
Harbor Health Care ETF
18.24%
Roundhill GLP-1 & Weight Loss ETF
16.7%
Health Care Select Sector SPDR Fund
14.06%
Proshares Ultra Health Care
13.57%
iShares U.S. Healthcare ETF
13.54%
Amplify Weight Loss Drug & Treatment ETF
11.93%
Fidelity MSCI Health Care Index ETF
11.73%
Goldman Sachs Future Health Care Equity ETF
10.84%
查看更多
VanEck Pharmaceutical ETF
占比47.56%
iShares U.S. Pharmaceuticals ETF
占比25.23%
Harbor Health Care ETF
占比18.24%
Roundhill GLP-1 & Weight Loss ETF
占比16.7%
Health Care Select Sector SPDR Fund
占比14.06%
Proshares Ultra Health Care
占比13.57%
iShares U.S. Healthcare ETF
占比13.54%
Amplify Weight Loss Drug & Treatment ETF
占比11.93%
Fidelity MSCI Health Care Index ETF
占比11.73%
Goldman Sachs Future Health Care Equity ETF
占比10.84%

分红派息

近5年累计派现 15.37B 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
Dec 08, 2025
LLY.NB Interim Cash Dividend of gross USD 1.73 paid on Mar 10, 2026 going ex on Feb 13, 2026
Feb 13, 2026
Mar 10, 2026
Feb 13, 2026
Oct 27, 2025
LLY.NB Final Cash Dividend of gross USD 1.5 paid on Dec 10, 2025 going ex on Nov 14, 2025
Nov 14, 2025
Dec 10, 2025
Nov 14, 2025
Jun 23, 2025
LLY.NB Interim Cash Dividend of gross USD 1.5 paid on Sep 10, 2025 going ex on Aug 15, 2025
Aug 15, 2025
Sep 10, 2025
Aug 15, 2025
May 05, 2025
LLY.NB Interim Cash Dividend of gross USD 1.5 paid on Jun 10, 2025 going ex on May 16, 2025
May 16, 2025
Jun 10, 2025
May 16, 2025
Dec 09, 2024
LLY.NB Interim Cash Dividend of gross USD 1.5 paid on Mar 10, 2025 going ex on Feb 14, 2025
Feb 14, 2025
Mar 10, 2025
Feb 14, 2025
Oct 28, 2024
LLY.NB Final Cash Dividend of gross USD 1.3 paid on Dec 10, 2024 going ex on Nov 15, 2024
Nov 15, 2024
Dec 10, 2024
Nov 15, 2024
Jun 24, 2024
LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Sep 10, 2024 going ex on Aug 15, 2024
Aug 15, 2024
Sep 10, 2024
Aug 15, 2024
May 06, 2024
LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Jun 10, 2024 going ex on May 15, 2024
May 16, 2024
Jun 10, 2024
May 15, 2024
Dec 08, 2023
LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Mar 08, 2024 going ex on Feb 14, 2024
Feb 15, 2024
Mar 08, 2024
Feb 14, 2024
Nov 01, 2023
LLY.NB Final Cash Dividend of gross USD 1.13 paid on Dec 08, 2023 going ex on Nov 14, 2023
Nov 15, 2023
Dec 08, 2023
Nov 14, 2023
查看更多

拆合股

公告日期
除权除息日
类型
比率
暂无数据
公告日期
除权除息日
类型
比率
暂无数据
KeyAI